Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPP2CA | P67775 | 7/20 | 1.00 |
| ▸ | PPP5C | P53041 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | PPP1CC | P36873 | 1/20 | 1.00 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.88 |
| ▸ | PTPA | Q15257 | 2/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15445020 | 1.00 | PPP2CA (1.00) | PPP2CAPPP5CALDH1A1THRBHPGD | |
| SCHEMBL15381941 | 0.92 | PPP2CA (0.90) | PPP2CAPPP5CALDH1A1THRBHPGD | |
| SCHEMBL15382081 | 0.92 | PPP2CA (1.00) | PPP2CAPPP5CALDH1A1THRBHPGD | |
| SCHEMBL889228 | 0.88 | PPP2CA (0.80) | PPP2CAPPP5CALDH1A1THRBHPGD | |
| SCHEMBL15381936 | 0.86 | PPP2CA (0.86) | PPP2CAPPP5CALDH1A1THRBHPGD | |
| SCHEMBL15381939 | 0.84 | PPP2CA (0.90) | PPP2CAPPP5CALDH1A1THRBHPGD | |
| SCHEMBL15381940 | 0.84 | PPP2CA (0.90) | PPP2CAPPP5CALDH1A1THRBHPGD | |
| SCHEMBL15444945 | 0.84 | PPP2CA (0.90) | PPP2CAPPP5CALDH1A1THRBHPGD | |
| SCHEMBL15444944 | 0.84 | PPP2CA (0.90) | PPP2CAPPP5CALDH1A1THRBHPGD | |
| SCHEMBL15445017 | 0.83 | PPP2CA (1.00) | PPP2CAPPP5CALDH1A1THRBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4673458-A1 | METHODS OF ENHANCING PRODUCTION OF METABOLITES IN BACTERIA | JOHN INNES CENTRE (GB) | 2026-01-07 | — | — | EP | claimed |
| EP-3966344-B1 | KINASE SCREENING ASSAYS | UNIV NEWCASTLE (GB) | 2025-06-25 | — | — | EP | claimed |
| WO-2024180095-A1 | METHODS OF ENHANCING PRODUCTION OF METABOLITES IN BACTERIA | JOHN INNES CENTRE (GB) | 2024-09-06 | — | — | WO | claimed |
| US-20220213524-A1 | KINASE SCREENING ASSAYS | THE UNIVERSITY OF NEWCASTLE UPON TYNE (GB) | 2022-07-07 | — | — | US | claimed |
| EP-3966344-A1 | KINASE SCREENING ASSAYS | University of Newcastle Upon Tyne (GB) | 2022-03-16 | — | — | EP | claimed |
| WO-2020225535-A1 | KINASE SCREENING ASSAYS | UNIVERSITY OF NEWCASTLE UPON TYNE (GB) | 2020-11-12 | — | — | WO | claimed |
| US-20150352131-A1 | Compositions and Methods for the Prevention and Treatment of Osteolysis and Osteoporosis | RHODE ISLAND HOSPITAL (US) | 2015-12-10 | — | — | US | claimed |
| US-20150038432-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RETINAL DEGENERATION | UNIVERSITE DE STRASBOURG (FR) | 2015-02-05 | — | — | US | claimed |
| EP-2817020-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RETINAL DEGENERATION | Université de Strasbourg (FR) | 2014-12-31 | — | — | EP | claimed |
| WO-2014113584-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF OSTEOLYSIS AND OSTEOPOROSIS | RHODE ISLAND HOSPITAL (US) | 2014-07-24 | — | — | WO | claimed |
| US-20110281942-A1 | Tautomycetin and Tautomycetin Analog Biosynthesis | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2011-11-17 | — | — | US | claimed |
| WO-2007102685-A1 | NOUA NOVEL IN VIVO PERFUSION METHOD FOR INDUCING DIFFERENTIAL SIGNALING IN AN ANIMAL | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2007-09-13 | — | — | WO | claimed |
| WO-2007015175-A2 | USE OF PP-1 INHIBITORS TO PREVENT MISSPLICING EVENTS | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2007-02-08 | — | — | WO | claimed |
| EP-1736154-A1 | Use of PP-1 inhibitors to prevent missplicing events | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2006-12-27 | — | — | EP | claimed |
| US-20060148060-A1 | Biomolecule transduction motif Mph-1-BTM and the use thereof | FORHUMANTECH. CO., LTD. (KR) | 2006-07-06 | — | — | US | claimed |
| WO-2005118797-A2 | BIOSYNTHETIC GENE CLUSTER FOR TAUTOMYCETIN | KOSAN BIOSCIENCES INCORPORATED (US) | 2005-12-15 | — | — | WO | claimed |
| US-6608045-B2 | Suppresses the expression of interleukin-2 | CHONG KUN DANG CORPORATION (KR) | 2003-08-19 | — | — | US | claimed |
| US-20030073737-A1 | Tolerance induction | COOKE NIGEL GRAHAM (CH) | 2003-04-17 | — | — | US | claimed |
| US-20010016599-A1 | STREPTOMYCES SP PRODUCING TAUTOMYCETIN AND IMMUNOSUPPRESSANT COMPRISING TAUTOMYCETIN AS ACTIVE INGREDIENT | CHONG KUN DANG CORPORATION (KR) | 2001-08-23 | — | — | US | claimed |
| WO-1999050388-A1 | STREPTOMYCES SP. PRODUCING TAUTOMYCETIN AND IMMUNOSUPPRESSANT COMPRISING TAUTOMYCETIN AS ACTIVE INGREDIENT | CHONG KUN DANG CORPORATION (KR) | 1999-10-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073737-A1 | Tolerance induction | HLA-DRB1, HLA-C, CD14 | PPP2CA 175/4885PPP5C 478/4885ALDH1A1 2969/4885 |
| US-20110281942-A1 | Tautomycetin and Tautomycetin Analog Biosynthesis | PTPRJ, PPP5C, MTMR1 | PPP2CA 20/4885PPP5C 2/4885ALDH1A1 2934/4885 |
| US-20010016599-A1 | STREPTOMYCES SP PRODUCING TAUTOMYCETIN AND IMMUNOSUPPRESSANT COMPRISING TAUTOMYCETIN AS ACTIVE INGREDIENT | CD69, IL2RA, IL2 | PPP2CA 2333/4885PPP5C 3339/4885ALDH1A1 3058/4885 |
| US-20150352131-A1 | Compositions and Methods for the Prevention and Treatment of Osteolysis and Osteoporosis | SOST, PTPN6, PTPN3 | PPP2CA 138/4885PPP5C 105/4885ALDH1A1 4885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.